Belgium's UCB to acquire Neurona Therapeutics for up to $1.15 billion
17/04/2026 18:07
April 17 (Reuters) - Belgium biopharmaceutical group UCB UCB.BR said on Friday that it will acquire U.S. based Neurona Therapeutics for up to $1.15 billion. (Reporting by Gursimran Kaur in Bengaluru; Editing by Shinjini Ganguli) ((GursimranKaur.Mehar@thomsonreuters.com;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside